Skip to main content

Advertisement

Log in

A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Purpose

To investigate the therapeutic response of patients with different types of bone metastases treated with combined radiotherapy and bisphosphonates.

Patients and methods

By using computed tomography 52 patients were grouped into groups of lytic, mixed and sclerotic bone lesions. All patients were treated with concomitant radiotherapy and ibandronate (10 monthly cycles) and underwent clinical and radiological evaluations prior to therapy and at 3, 6 and 10 months of follow up.

Results

At baseline there were statistically significant differences between the three groups for all the evaluated parameters. From 3 months onwards differences were leveled out. Statistically significant improvements were noted at all time points of evaluation for all groups in parameters such as pain (0–10), quality of life (QOL-physical functioning, 0–100) and Karnofsky performance status (KPS). The average pain score for the lytic group was reduced from 8.1 to 1.5 points at 3 months. The corresponding reductions for the mixed and sclerotic groups were from 6.2 to 0.5 and from 4.4 to 0.3 points respectively. Complete pain responses were >76.4% at all time points for all groups. Opioid consumption was also markedly reduced. Overall, the highest clinical response was noted for the lytic group, even though the mean values of pain, QOL and KPS were worse than those of the two other groups at all time points (apart from pain score at 10 months). The percentage of patients of the lytic group experiencing a complete pain response was the least of the three groups during follow up. At 10 months bone density was almost tripled for the lytic and almost doubled for the mixed group.

Conclusions

Even though the therapeutic outcome for the three groups was similar, the degree of clinical response and reossification differed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(S8):1588–1594

    Article  PubMed  CAS  Google Scholar 

  2. Sze WM, Shelley MD, Held I, et al (2003) Palliation of metastatic bone pain: single versus multifraction radiotherapy—a systematic review of randomized trials. Clin Oncol 15:345–352

    Article  CAS  Google Scholar 

  3. Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321–327

    Article  PubMed  CAS  Google Scholar 

  4. Hoskin PJ, Stratford NRL, Folkes LK, et al (2000) Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 355:1428–1429

    Article  PubMed  CAS  Google Scholar 

  5. Body JJ, Diel IJ, Lichinitser MR, et al (2003) Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14:1399–1405

    Article  PubMed  Google Scholar 

  6. Pavlakis N, Stocker M (2002) Bisphosphonates for breast cancer. In: The cochrane library, issue 1. Update Software, Oxford

  7. Rosen L, Gordon D, Tchekmedyian S, et al (2002) Zoledronic acid (Zol) significally reduces skeletal related events in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 21:295

    Google Scholar 

  8. Masasachia P, Weinreb M, Balena R, et al (1996) Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19:281–290

    Article  Google Scholar 

  9. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97–106

    Article  PubMed  CAS  Google Scholar 

  10. Rogers MJ, Gordon S, Benford HL, et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978

    Article  PubMed  CAS  Google Scholar 

  11. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176

    Article  PubMed  CAS  Google Scholar 

  12. Vassiliou V, Kalogeropoulou C, Petsas T, et al (2007) Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between the clinical status of patients and the type of bone metastases? Clin Exp Metastasis (in press) doi:10.1007/s10585-007-9056-z

  13. Vassiliou V, Kalogeropoulou C, Christopoulos C, et al (2007) Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67(1):264–272

    PubMed  CAS  Google Scholar 

  14. Fayers PM, Aaronson NK, Bjordal K, et al (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC Quality of life group, Brussels

    Google Scholar 

  15. McQuay HJ, Collins SL, Caroll D, et al (2001) Radiotherapy for the palliation of painful bone metastases (cochrane review). In: The cochrane library. Update software, Oxford

  16. Falkmer U, Jarhult J, Wersall P, et al (2003) A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 42(5–6):620–633

    Article  PubMed  Google Scholar 

  17. Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseus metastases. Final results of the study by the radiation therapy oncology group. Cancer 50:893–899

    Article  PubMed  CAS  Google Scholar 

  18. Salazar OM, Sandhut T, da Motta MW, et al (2001) Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the international atomic energy agency (IAEA). Int J Radiat Oncol Biol Phys 50(3):765–775

    Article  PubMed  CAS  Google Scholar 

  19. Body JJ, Diel IJ, Bell R, et al (2004) Oral ibandronate improved pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111:306–312

    Article  PubMed  CAS  Google Scholar 

  20. Diel IJ, Body JJ, Lichinitser MR, et al (2004) Improved quality of life after long term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40:1704–1712

    Article  PubMed  CAS  Google Scholar 

  21. Kouloulias EV, Kouvaris RJ, Antypas C, et al (2003) An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques. Strahlenther Onkol 179:471–479

    PubMed  Google Scholar 

  22. Kouloulias V, Matsopoulos G, Kouvaris J, et al (2003) Radiotherapy in conjuction with intravenous infusion of 180mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys 57(1):143–157

    Article  PubMed  CAS  Google Scholar 

  23. Firusian N, Mellin P, Schmidt CG (1976) Results of 89-strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: A preliminary report. J Urol 116:764

    PubMed  CAS  Google Scholar 

  24. Quilty PM, Kirk D, Bolger JJ, et al (1994) A comparison of the palliative effects of strontium 89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33

    Article  PubMed  CAS  Google Scholar 

  25. Buchali K, Correns HJ, Schuerer M, et al (1988) Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14:349

    Article  PubMed  CAS  Google Scholar 

  26. Reddy EK, Robinson RG, Mansfield CM (1986) Strontium 89 for palliation of bone metastases. J Natl Med Assoc 78:27

    PubMed  CAS  Google Scholar 

  27. Storto G, Klain M, Paone G, et al (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41

    Article  PubMed  CAS  Google Scholar 

  28. Blitzer P (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. Cancer 55:1468–1472

    Article  PubMed  CAS  Google Scholar 

  29. Ratanatharathorn V, Powers WE, Moss WT, et al (1999) Bone metastases: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 44:1–18

    Article  PubMed  CAS  Google Scholar 

  30. Wu JS, Wong R, Johnson M, et al (2003) Meta-analysis of the dose fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605

    Article  PubMed  Google Scholar 

  31. Osoba D, Rodrigues G, Myles J, et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144

    PubMed  CAS  Google Scholar 

  32. Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11:1699–1707

    PubMed  CAS  Google Scholar 

  33. Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(Suppl 3):834–839

    Article  PubMed  Google Scholar 

  34. Chow E, Holden L, Rubenstein J, et al (2004) Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy—a feasibility study. Radiother Oncol 70:291–294

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dimitrios Kardamakis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vassiliou, V., Kalogeropoulou, C., Giannopoulou, E. et al. A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 24, 169–178 (2007). https://doi.org/10.1007/s10585-007-9066-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-007-9066-x

Keywords

Navigation